Recurrent B Acute Lymphoblastic Leukemia Recruiting Phase 2 Trials for Inotuzumab ozogamicin (DB05889)

IndicationStatusPhase
DBCOND0107328 (Recurrent B Acute Lymphoblastic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03739814Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaTreatment
NCT03441061Inotuzumab Ozogamicin in Treating Participants With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseTreatment